Neurodegeneration – News and Features

Duke researchers have found a common variation in genes puts women who are under chronic stress at risk for increased depressive symptoms, but has the exact opposite effect in men.

A group of the nation’s leaders in stem cell biology announced formation of a new biotechnology company developing drugs to control cell fate.

The Company claims that its adult stem cell therapies provide a safer approach at treating neurodegenerative diseases than competitive therapies that rely on embryonic stem cells.

The testing of PLX cells showed a reduction of TNF-a and interferon-? inflammatory cytokines that are involved in the pathogenesis of autoimmune disorders.

Results support four-fold higher arimoclomol dose for planned Phase IIb efficacy trial for ALS.

Researchers from Wisconsin and Japan had announced that they had reprogrammed adult human cells to act like embryonic stem cells.

A treatment developed at Jerusalem's Hadassah-University Hospital, still in the research stage, has been tested on 25 multiple sclerosis and ALS patients.

Researchers reports the genetic reprogramming of human skin cells to create cells indistinguishable from embryonic stem cells in a paper to be published online.

Neuralstem has exclusively licensed the "Spinal Multisegmental Cell and Drug Delivery System," invented by Dr. Martin Marsala at UCSD.

Scientists have derived embryonic stem cells by reprogramming of genetic material from skin cells while studying rhesus macaque monkeys.